MSUCN nanocarriers that combine immunotherapy and photodynamic therapy, enabling synergistic anti-cancer therapy by actively targeting tumor cells with folic acid and stimulating the immune response by generating reactive oxygen species and inhibiting the IDO pathway. The gene discussed is IDO1; the disease is neoplasm.